The novel α7 nAChR partial agonist encenicline did not attenuate nicotine withdrawal-associated cognitive deficits in abstinent human smokers, as reflected by similar deficits in treated and untreated abstinent smokers when tested using the Conners Continuous Performance Task to assess attention and response inhibition and using the N-Back task to measure working memory (Schuster et al., 2018). This evidence concerns the gene CHRNA7 and Cognitive impairment.